Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007631 · ClinicalTrials.gov registry record · Phase 3
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
A Phase 3 study of Carcinoma, Squamous Cell and Skin Neoplasms, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,131
- Enrollment target
- 7
- Study locations
NCT00007631: Completed Phase 3 study of Carcinoma, Squamous Cell and Skin Neoplasms, sponsored by US Department of Veterans Affairs.
NCT00007631 is a Phase 3 study of Carcinoma, Squamous Cell and Skin Neoplasms that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 1,131 participants, above the 180-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (528% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00007631, a Phase 3 study of Carcinoma, Squamous Cell and Skin Neoplasms, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,131 participants
- Enrollment target
- 7
- Study locations
Study Summary
One-third of all malignancies in the United States (approximately one million cases diagnosed annually) are nonmelanoma skin cancer (NMSC). NMSC causes considerable morbidity, economic burden, facial deformity and at least 1,000 deaths annually. Prevention of these malignancies with a topical agent free of serious side effects would confer substantial public health benefit. Three hundred fifty thousand veterans were expected to develop NMSC in 1994. NMSC is one of the most common conditions requiring dermatologic care in the VA system. Topical tretinoin has been used extensively to treat photoaged skin. Retinoids administered orally in high doses appear to be effective in chemoprevention of nonmelanoma skin cancer but have unacceptable toxicity. In this study, 1131 patients with a recent history of squamous cell and/or basal cell carcinoma were enrolled at six participating centers over a four-year period and were randomly assigned to either 0.1% tretinoin cream or placebo. They were followed for a minimum of two years to determine if topical tretinoin is effective in reducing the risk of new occurrences.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Tretinoin 0.1% cream or placebo
Study Locations (7)
Arizona
- Carl T. Hayden VA Medical Center - Phoenix
California
- VA Medical Center, Long Beach - Long Beach
Florida
- VA Medical Center, Miami - Miami
Illinois
- Edward Hines, Jr. VA Hospital - Hines
North Carolina
- VA Medical Center, Durham - Durham
Oklahoma
- VA Medical Center, Oklahoma City - Oklahoma City
Rhode Island
- VA Medical Center, Providence - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,131 participants |
| Start Date | 1998-03 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
What the finished NCT00007631 record still lists
NCT00007631 is an interventional study that assigns participants to a tested intervention. Its 1,131 participants enrollment target places it among the larger protocols in the corpus, above the 180-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (528% higher).
The record links to 3 conditions, with Carcinoma, Squamous Cell appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00007631 lists 7 locations in 7 states (Arizona, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00007631 about?
NCT00007631 is a clinical study titled "Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer". One-third of all malignancies in the United States (approximately one million cases diagnosed annually) are nonmelanoma skin cancer (NMSC). NMSC causes considerable morbidity, economic burden, facial deformity and at least 1,000 deaths annually. Prevention of these malignancies with a topical agent ...
What is the current status of trial NCT00007631?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,131 participants. The study started on 1998-03. Estimated completion is 2006-07.
What conditions does trial NCT00007631 study?
This clinical trial studies the following conditions: Carcinoma, Squamous Cell, Skin Neoplasms, Carcinoma, Basal Cell.
What interventions are being tested in trial NCT00007631?
The interventions under investigation include: Placebo (OTHER), Tretinoin 0.1% cream or placebo (DRUG).
Who is sponsoring clinical trial NCT00007631?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00007631 being conducted?
This trial has 7 study locations across Arizona, California, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Squamous Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00007631's enrollment target sits among peer trials
1,131 1st of 14 higher than 14 of 14 other Carcinoma, Squamous Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Squamous Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
COMPLETED · Phase 3
-
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
RECRUITING · Phase 1
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RECRUITING · Phase 1
-
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
RECRUITING
-
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
RECRUITING · Phase 2
-
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
- NCT06895148 · 1,125 participants · NA
ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia